These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 38091227)

  • 1. An epicutaneous therapeutic pollen-allergen extract delivery system in an allergic rhinitis mouse model: based on allergen loading on DC-specific aptamers conjugated nanogolds.
    Pordel S; Haghnavaz N; Rezaee M; Shobeiri SS; Ansari B; Dashti M; Moghadam M; Khorrami M; Sankian M
    Immunol Res; 2024 Jun; 72(3):460-475. PubMed ID: 38091227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dc-specific aptamer decorated gold nanoparticles: A new attractive insight into the nanocarriers for allergy epicutaneous immunotherapy.
    Koushki K; Varasteh AR; Shahbaz SK; Sadeghi M; Mashayekhi K; Ayati SH; Moghadam M; Sankian M
    Int J Pharm; 2020 Jun; 584():119403. PubMed ID: 32387307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Hydrogel Based Allergen-Coated Gold Nanoparticles for Topical Administration: A Possible Epicutaneous Immunotherapy in Pollen-Sensitized Mice?
    Pordel S; Rezaee M; Moghadam M; Sankian M
    Immunol Invest; 2024 Apr; 53(3):523-539. PubMed ID: 38166585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DC-targeted gold nanoparticles as an efficient and biocompatible carrier for modulating allergic responses in sublingual immunotherapy.
    Sadeghi M; Koushki K; Mashayekhi K; Ayati SH; Keshavarz Shahbaz S; Moghadam M; Sankian M
    Int Immunopharmacol; 2020 Sep; 86():106690. PubMed ID: 32585607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methods for Experimental Allergen Immunotherapy: Subcutaneous and Sublingual Desensitization in Mouse Models of Allergic Asthma.
    Hesse L; Petersen AH; Nawijn MC
    Methods Mol Biol; 2021; 2223():295-335. PubMed ID: 33226602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with a recombinant hybrid molecule alleviates allergic responses more efficiently than an allergenic cocktail or pollen extract in a model of chenopodium album allergy.
    Nouri HR; Sankian M; Afsharzadeh D; Varasteh A
    Int Arch Allergy Immunol; 2013; 161(4):325-32. PubMed ID: 23689669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant Art v4.01 protein produces immunological tolerance by subcutaneous immunotherapy in a wormwood pollen-driven allergic asthma female mouse model.
    Wang T; Chi J; Li Z; Zhang Y; Wang Y; Ding M; Zhou B; Gui J; Li Q
    PLoS One; 2024; 19(6):e0280418. PubMed ID: 38941291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sublingual dendritic cells targeting by aptamer: Possible approach for improvement of sublingual immunotherapy efficacy.
    Keshavarz Shahbaz S; Varasteh AR; Koushki K; Ayati SH; Mashayekhi K; Sadeghi M; Moghadam M; Sankian M
    Int Immunopharmacol; 2020 Aug; 85():106603. PubMed ID: 32485357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral administration of allergen extracts from mugwort pollen desensitizes specific allergen-induced allergy in mice.
    Ma WJ; Bao MJ; Zhu JP; Yao HY; Xie YC; Guan Y; Li FF; Dong XW; Zheng YM; Xie QM
    Vaccine; 2012 Feb; 30(8):1437-44. PubMed ID: 22240342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible relationship between systemic side effects and sensitization to rPar j 2 in allergic patients submitted to an ultra-rush (20 min) sublingual immunotherapy and selected by component resolved diagnosis.
    Rossi RE; Monasterolo G; Coco G; Operti D
    Int Arch Allergy Immunol; 2005 Oct; 138(2):105-10. PubMed ID: 16174987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model.
    Siebeneicher S; Reuter S; Wangorsch A; Krause M; Foetisch K; Heinz A; Naito S; Reuter A; Taube C; Vieths S; Scheurer S; Toda M
    Allergy; 2015 Dec; 70(12):1559-68. PubMed ID: 26304061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study.
    Spertini F; DellaCorte G; Kettner A; de Blay F; Jacobsen L; Jutel M; Worm M; Charlon V; Reymond C
    J Allergy Clin Immunol; 2016 Jul; 138(1):162-8. PubMed ID: 27373329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant Fusion Allergens, Cry j 1 and Cry j 2 from Japanese Cedar Pollen, Conjugated with Polyethylene Glycol Potentiate the Attenuation of Cry j 1-Specific IgE Production in Cry j 1-Sensitized Mice and Japanese Cedar Pollen Allergen-Sensitized Monkeys.
    Fujimura T; Fujinami K; Ishikawa R; Tateno M; Tahara Y; Okumura Y; Ohta H; Miyazaki H; Taniguchi M
    Int Arch Allergy Immunol; 2015; 168(1):32-43. PubMed ID: 26524293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific allergen immunotherapy attenuates allergic airway inflammation in a rat model of Alstonia scholaris pollen induced airway allergy.
    Datta A; Moitra S; Hazra I; Mondal S; Das PK; Singh MK; Chaudhuri S; Bhattacharya D; Tripathi SK; Chaudhuri S
    Int Immunopharmacol; 2016 Jan; 30():111-120. PubMed ID: 26667977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transcutaneous delivery of CpG-adjuvanted allergen via laser-generated micropores.
    Hessenberger M; Weiss R; Weinberger EE; Boehler C; Thalhamer J; Scheiblhofer S
    Vaccine; 2013 Jul; 31(34):3427-34. PubMed ID: 23273971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous and Sublingual Immunotherapy in a Mouse Model of Allergic Asthma.
    Hesse L; Nawijn MC
    Methods Mol Biol; 2017; 1559():137-168. PubMed ID: 28063043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A recombinant
    Babayeva M; Tabynov K; Nurpeisov T; Fomin G; Renukaradhya GJ; Petrovsky N; Tabynov K
    Front Immunol; 2022; 13():983621. PubMed ID: 36439113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
    Rossi RE; Monasterolo G
    Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determinants of efficacy and safety in epicutaneous allergen immunotherapy: summary of three clinical trials.
    Senti G; von Moos S; Tay F; Graf N; Johansen P; Kündig TM
    Allergy; 2015 Jun; 70(6):707-10. PubMed ID: 25704072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epicutaneous immune modulation with Bet v 1 plus R848 suppresses allergic asthma in a murine model.
    Siebeneicher S; Reuter S; Krause M; Wangorsch A; Maxeiner J; Wolfheimer S; Schülke S; Naito S; Heinz A; Taube C; Vieths S; Scheurer S; Toda M
    Allergy; 2014 Mar; 69(3):328-37. PubMed ID: 24329861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.